Multiple sclerosis (MS) is a neurological disease that affects about 1 million people in the United States. Your brain contains a type of cell called a neuron, and neurons are coated in a layer of ...

A Phase 2 clinical trial testing PIPE-307, an MS experimental therapy designed to promote myelin repair, failed to meet its ...

Join the School of Medicine’s Department of Population and Quantitative Health Sciences to learn about the options available with an MS in clinical research. A webinar will be held Sunday, Dec. 20, at ...

The poster session at the Americas Committee for Research and Treatment in Multiple Sclerosis (ACTRIMS) Forum 2024 dedicated a section to emerging developments in the use of artificial intelligence ...

"Routine cognitive assessments should be integrated into clinical practice, allowing for early detection and intervention." — Dejan Jakimovski, MD, PhD, Research Assistant Professor, Department of ...

MS is the most common demyelinating disease with an estimated prevalence of 3 in 1000 in the United States. It affects approximately 740,000 individuals in the United States and 2.5 million globally.

Dr. Bhargava is an Associate Professor of Neurology at Johns Hopkins University School of Medicine. After obtaining his medical degree from Christian Medical College in Vellore, India, Dr. Bhargava ...

The Combined Bachelor’s/Master’s Degree program (CBM) is intended for highly motivated current CWRU undergraduate students who are candidates for any bachelor's ...

The only pharmacy school based program of its kind in the country, our MS in Clinical and Translational Therapeutics provides a valuable opportunity to be involved in research and training to combat ...

Multiple sclerosis (MS) is characterized by a broad array of symptoms. Despite this variability, most individuals with MS will exhibit a distinct set of symptoms during their initial clinical attack.